Takeover target: Is the German biotech industry facing a sell-off?
After Tubulis, biotech hopeful ITM is also going to a foreign pharmaceutical company. Whether such sales mean a sell-off is controversial. The industry continues to lack one thing above all else.
German biotech companies are attracting takeover bids, with recent examples including ITM, acquired by Australia's Telix for over $1.65 billion, and Tubulis, bought by US pharma giant Gilead for over $3 billion. The deals have raised concerns that German firms are developing new therapies while foreign companies reap the benefits.
The German biotech industry's financing volume was €864 million until September, 23% down from the previous year, according to the industry association Bio Deutschland. Experts warn that without more growth capital and a functioning stock market access, German biotech companies may be forced to seek large foreign partners.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.